PURPOSE: Specific features of different populations may influence the results of prognostic indexes. Along with its Global Equation, SAPS 3 comprises seven other equations developed to consider such regional features. This study intends to evaluate the performance of these equations in the same population in a general intensive care unit in Brazil.
METHODS: We analyzed prospectively collected data from January 1st to August 31st, 2006. From the 544 admissions, we excluded 42 (7.72%) readmissions. In the 502 included patients, we analyzed the Standardized Mortality Rate (SMR), calibration through the Hosmer-Lemeshow® test, and discrimination through the under the ROC curve area (aROC). The endpoint was death or hospital discharge. Calculations were achieved through the EXCEL 2000 Microsoft Corporation and MedCalc Version 22.214.171.124 Frank Schoonjans programs. The presented Confidence Interval (CI) is 95%.
RESULTS: The calculated SMR for the different equations was: .8182 (CI .6664 –.9944) for Central/South America; 1.0051 (CI .8145 –1.2151) for Eastern Europe; 1.0385 (CI .8459 –1.2622) for Southern Europe; 1.0644 (CI .8670–1.2937) for Global; 1.1415 (CI .9297–1.3873) for North Europe; 1.1608 (CI .9454–1.4108) for Australasia; 1.1760 (CI .9578–1.4293) for North America, and 1.2590 (CI 1.0254–1.5302) for Western Europe. Discrimination was adequate for Eastern Europe (P= .4777), Global (P= .1110), North Europe (P= .0851) Southern Europe (P= .0839) Central/South America (P=.0578) and inadequate for Australasia (P=.0288) Western Europe (P= .0073) and North America (P= .0011). Discrimination was adequate for all studied equations (aROC > .8).
CONCLUSION: SAPS 3 Global, Central/South America, Eastern Europe, North Europe, and Southern Europe equations showed similar performances in the studied population.
CLINICAL IMPLICATIONS: SAPS 3 Global, Central/South America, Eastern Europe, North Europe, and Southern Europe might be applicable to the studied population.
DISCLOSURE: Carlos Alves, No Financial Disclosure Information; No Product/Research Disclosure Information